source
- GSK CEO outlines £1.9bn cost-saving drive and aims to launch 20 Phase 3 trials by year-endGSK chief executive Luke Miels presented a three‑year plan to make the company more agile and generate significant cost efficiencies. The strategy targets £1.9 billion in annual savings by 2029, wi…
- FDA staff raise concerns over Replimune's skin cancer drug dataFDA staff have reiterated concerns that Replimune's investigational skin cancer therapy lacks sufficient data for approval. The agency highlighted the single-arm trial, in which patients previousl…